Author: Natalia Fintelman-Rodrigues; Carolina Q. Sacramento; Carlyle Ribeiro Lima; Franklin Souza da Silva; André C. Ferreira; Mayara Mattos; Caroline S. de Freitas; Vinicius Cardoso Soares; Suelen da Silva Gomes Dias; Jairo R. Temerozo; Milene Miranda; Aline R. Matos; Fernando A. Bozza; Nicolas Carels; Carlos Roberto Alves; Marilda M. Siqueira; Patrícia T. Bozza; Thiago Moreno L. Souza
Title: Atazanavir inhibits SARS-CoV-2 replication and pro-inflammatory cytokine production Document date: 2020_4_5
ID: 6zk0ioep_23
Snippet: In these two decades of the 21st century, the human vulnerability to emerging viral diseases has been notable 24 . The emergence of infectious disease highlights the undeniable fact that existing countermeasures are inefficient to prevent virus spill over and diseases outbreak. Preclinical data on the susceptibility of an emerging virus to clinically approved drugs can allow for the rapid mobilization of resources towards clinical trials 8 . This.....
Document: In these two decades of the 21st century, the human vulnerability to emerging viral diseases has been notable 24 . The emergence of infectious disease highlights the undeniable fact that existing countermeasures are inefficient to prevent virus spill over and diseases outbreak. Preclinical data on the susceptibility of an emerging virus to clinically approved drugs can allow for the rapid mobilization of resources towards clinical trials 8 . This approach proved feasible for combating the Zika, yellow fever and chikungunya outbreaks experienced in Brazil over the past 5 years, when our group demonstrated that sofosbuvir, a blockbuster drug against hepatitis C, could represent a compassionate countermeasure against these diseases [25] [26] [27] [28] [29] .
Search related documents:
Co phrase search for related documents- chikungunya yellow fever and viral disease: 1
- chikungunya yellow fever and yellow fever: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31
- clinical trial and emerge virus: 1
- clinical trial and infectious disease: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61
- clinical trial and outbreak disease: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38
- clinical trial and rapid mobilization: 1
- clinical trial and viral disease: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37
- clinical trial and yellow fever: 1, 2, 3, 4, 5
Co phrase search for related documents, hyperlinks ordered by date